Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease

Circulation. 2019 Aug 13;140(7):618-620. doi: 10.1161/CIRCULATIONAHA.119.041730. Epub 2019 Jun 7.

Authors

Affiliations

¹ Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (S.V.A., M.K.).
² Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (J.A.D.).
³ The Cardiometabolic Disorders Unit, Icahn School of Medicine at Mount Sinai, New York (R.S.R.).
⁴ Department of Medicine, Baylor College of Medicine and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (C.M.B.).
⁵ Baim Institute for Clinical Research, Boston, MA (Y.L., C.P.C.).
⁶ Amgen Inc, Thousand Oaks, CA (K.E.M., S.A., M.E-D.).
⁷ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.L.B., C.P.C.).
⁸ The George Institute for Global Health, Sydney, Australia (M.K.).

PMID: 31174429
DOI: 10.1161/CIRCULATIONAHA.119.041730

No abstract available

Keywords: coronary artery disease; diabetes mellitus; quality of care.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Atherosclerosis / blood*
Atherosclerosis / epidemiology
Atherosclerosis / therapy
Cardiovascular Diseases / blood
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / therapy
Cholesterol, LDL / blood*
Diabetes Mellitus / blood*
Diabetes Mellitus / epidemiology
Diabetes Mellitus / therapy
Disease Management
Dyslipidemias / blood*
Dyslipidemias / epidemiology
Dyslipidemias / therapy
Humans
Practice Guidelines as Topic / standards*
Risk Reduction Behavior*

Substances

Cholesterol, LDL